Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics

The majority of ovarian cancer patients present with advanced disease and despite aggressive treatment, prognosis remains poor. Response to first-line carboplatin-containing chemotherapy is usually good, however, recurrence rates and subsequent chemoresistance are very high and ultimately responsible for the fatal outcome of the disease. To improve treatment outcomes pre-clinical models that can predict individual patient response to 1st line chemotherapy and novel therapeutics are urgently required.

Source: Cancer Letters - February 6, 2018 Category: Cancer & Oncology Authors: Carmela Ricciardelli, Noor A. Lokman, Ilhamjan Sabit, Kavyadharshini Gunasegaran, Wendy M. Bonner, Carmen E. Pyragius, Anne M. Macpherson, Martin K. Oehler Source Type: research